Temozolomide sensitivity of malignant glioma cell lines - a systematic review assessing consistencies between in vitro studies.

Temozolomide sensitivity reported in comparable studies was not consistent between or within malignant glioma cell lines. Drug discovery science performed on these models cannot reliably inform clinical translation. A consensus model of reporting can maximise reproducibility and consistency among in vitro studies.